TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8916244
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (outpatient setting)
Study: 1841578
Drug: Mitomycin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin (0.2 mg) applied once during trabeculectomy
Study: 1841578
Drug: Fluorouracil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil (5 mg) injected subconjunctivally 10 times in 2 weeks after surgery
Study: 6357204
Drug: Orgotein (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orgotein (2 mg)
Study: 18824917
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (30 ppm) + glucocorticoids (2 mg/kg)
Study: 18824917
Drug: Placebo (nitrogen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (nitrogen) + glucocorticoids (2 mg/kg)
Study: 11803256
Drug: drug‐free W/O
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug‐free W/O vehicle
Study: 10332446
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral paroxetine as needed 3 to 4 hours before planned intercourse (Study 1)
Study: 10332446
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg paroxetine daily for 3 weeks and then 20 mg paroxetine as needed for 4 weeks (Study 2)
Study: 10332446
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 3 weeks and then placebo as needed for 4 weeks (Study 2)
Study: 10332446
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily and placebo as needed (Study 2)
Study: 8750371
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of ardeparin
Study: 29742189
Drug: Nutrafol® Women's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrafol® Women's Capsules (active treatment)
Study: 25027424
Drug: Norvancomycin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norvancomycin and heparin saline mixture
Study: 25027424
Drug: Heparin saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin saline
Study: 22318947
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg/day with a 36-h interval)
Study: 20558919
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of LAM plus ADV combination therapy
Study: 20558919
Drug: Overlap/switch to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overlap/switch to adefovir dipivoxil (ADV) monotherapy
Study: 20558919
Drug: Overlap/switch to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overlap/switch to ADV monotherapy
Study: 21418991
Drug: rhIL‐11 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL‐11 injection
Study: 12110838
Drug: Venom immunotherapy
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venom immunotherapy (VIT)
Study: 9542482
Drug: DMP 728
Normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMP 728 at doses of 0.05 to 0.9 mg
Study: 9542482
Drug: DMP 728
Normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMP 728 at doses up to 0.6 mg
Study: 9542482
Drug: DMP 728
Normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMP 728 at 0.9 mg
Study: 9542482
Drug: DMP 728
Normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMP 728 at doses of 1.5 mg to 3.9 mg
Study: 9542482
Drug: DMP 728
Normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMP 728 (all dose groups)
Study: 9542482
Drug: DMP 728
Normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMP 728 (all doses)
Study: 15374302
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Aramexe retard
Study: 15374302
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Hydergine
Study: 3391873
Drug: Erythromycin acistrate
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin acistrate (EA) 400 mg tid for 10 days
Study: 3391873
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate (ES) 500 mg tid for 10 days
Study: 31755220
Drug: Early combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combination (entecavir plus Peg‐interferon [IFN]α‐2a co‐administration during year 1)
Study: 31755220
Drug: Late combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late combination (addition of Peg‐IFNα‐2a for 48 weeks after 1 year of entecavir)
Study: 31755220
Drug: Nucleos(t)ide analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleos(t)ide analogue (NA) monotherapy
Study: 31755220
Drug: Non-antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antiviral treatment
Study: 29633918
Drug: Novel device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel device for preoperative skin preparation
Study: 29633918
Drug: Current techniques
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current techniques of skin preparation
Study: 27506926
Drug: High-sensitivity troponin
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity troponin T (hs‐TnT) reporting among patients with troponin levels <30 ng/L
Study: 27506926
Drug: Standard reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard reporting (std‐report) among patients with troponin levels <30 ng/L
Study: 23657308
Drug: Alanyl-glutamine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanyl-glutamine (24 g/day)
Study: 23657308
Drug: Placebo (glycine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glycine, 25 g/day)
Study: 20734845
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Mallampati test, Patila test, and ULBT test
Study: 19006471
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g P‐OM3 plus 40 mg rosuvastatin
Study: 16015260
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E co-supplementation with multi-drug therapy (MDT)
Study: 16015260
Drug: Multi-drug therapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug therapy (MDT)
Study: 12970290
Drug: Oral 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17beta‐estradiol 2 mg combined with trimegestone 0.5 mg (E(2)+T)
Study: 12970290
Drug: Oral 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17beta‐estradiol 2 mg combined with dydrogesterone 10 mg (E(2)+D)
Study: 1387369
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 mg twice daily for 12 months)
Study: 30776296
Drug: rhG‐CSF (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG‐CSF (130 μg daily subcutaneous injections for a maximum of 9 weeks)
Study: 30776296
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical appearing injections for a maximum of 9 weeks)
Study: 16050428
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen patches (100 microg per day)
Study: 2484789
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment of 8 Gy
Study: 793780
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ketoprofen per day
Study: 793780
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg indomethacin per day
Study: 31717901
Drug: Fibre supplementation
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplementation (twice-a-day)
Study: 21277837
Drug: Aceclofenac-CR (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac-CR (n = 143) once daily
Study: 21277837
Drug: Conventional aceclofenac
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional aceclofenac (n = 142) twice daily
Study: 11778097
Drug: Continuous cervical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous cervical plexus block with ropivacaine 0.75% 2.5 mg/kg
Study: 11778097
Drug: Continuous cervical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous cervical peridural anaesthesia with ropivacaine 0.5% 0.9 mg/kg and fentanyl 50-100 g
Study: 9424681
Drug: vecuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.01 mg/kg
Study: 7690527
Drug: Terfenadine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 120 mg bid
Study: 7690527
Drug: Terfenadine, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 240 mg bid
Study: 7690527
Drug: Ketotifen, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen, 2 mg bid
Study: 24832787
Drug: Circulating tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating tumor cells (CTCs) detected before chemotherapy
Study: 24832787
Drug: Circulating tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating tumor cells (CTCs) detected after chemotherapy
Study: 24832787
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of at least five CTCs per 30 mL blood
Study: 24832787
Drug: Persisting CTCs
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persisting CTCs after chemotherapy
Study: 12692962
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with radiation therapy of the involved field (specific chemotherapy regimen not detailed, but mentions CHOP cycles).
Study: 12692962
Drug: Short-course chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course chemotherapy (3 cycles of CHOP) for low bulk tumors.
Study: 12692962
Drug: Full-course chemotherapy
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-course chemotherapy (6-8 cycles of CHOP) for larger tumors.
Study: 10779656
Drug: Oral dextromethorphan
Normalized name: dextromethorphan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextromethorphan 150 mg
Study: 3134905
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate treatment
Study: 26887521
Drug: Improved treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved treatment group (400 µg folic acid daily from the day before the first dose to 21 days after the last dose, 500 µg vitamin B12 injection one day before the first dose and before each therapy cycle)
Study: 26887521
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (400 µg folic acid daily for 7 days before the first dose and continued until 21 days after the last dose, 1000 µg vitamin B12 injection at 7 days before the first dose and once per cycle for 3 cycles after the last dose)
Study: 26887521
Drug: Improved treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved treatment group
Study: 18312649
Drug: Self‐Administered Mailed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐Administered Mailed Questionnaire (SAMQ)
Study: 16970600
Drug: Weight-based RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based RBV dosing
Study: 8881626
Drug: Ketamine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 3 mg kg-1 nasally (group IN3)
Study: 8881626
Drug: Ketamine 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 9 mg kg-1 nasally (group IN9)
Study: 8881626
Drug: Ketamine 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 9 mg kg-1 rectally (group IR9)
Study: 8881626
Drug: Ketamine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 3 mg kg-1 i.v. (group IV3)
Study: 8881626
Drug: Rectal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal ketamine (group IR9)
Study: 8881626
Drug: Norketamine after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norketamine after nasal administration
Study: 3890924
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg daily, doubled after 3 months if inadequate response)
Study: 3890924
Drug: Griseofulvin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (500 mg daily, doubled after 3 months if inadequate response)
Study: 29338639
Drug: Continuous Passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Passive Motion (CPM) combined with Complete Decongestive Therapy (CDT)
Study: 29338639
Drug: Complete Decongestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete Decongestive Therapy (CDT) alone
Study: 24215171
Drug: ABT-288 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-288 (10 dose levels, from 1 to 60 mg once daily for 14 days)
Study: 20929341
Drug: Margarine supplemented
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margarine supplemented with EPA and DHA (targeted additional daily intake of 400 mg of EPA-DHA)
Study: 20929341
Drug: Margarine supplemented
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margarine supplemented with ALA (targeted additional daily intake of 2 g of ALA)
Study: 15763436
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion therapy
Study: 9987142
Drug: Full-dose Mérieux
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose Mérieux BCG vaccine (lot E0650)
Study: 9987142
Drug: Full-dose Mérieux
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose Mérieux BCG vaccine (lot E0624)
Study: 9987142
Drug: Full-dose WHO-reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose WHO-reference vaccine (Tokyo strain 172)
Study: 9987142
Drug: 1/10 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/10 dose WHO-reference vaccine
Study: 7489845
Drug: Lovastatin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (n = 16; mean dose 30.0 +/- 12.6 mg/day)
Study: 2227746
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Ruscus extract (4 to 6 g of cream containing 64 to 96 mg Ruscus extract)
Study: 2227746
Drug: Placebo (base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (base of the cream)
Study: 29653541
Drug: TARGIT-IORT (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARGIT-IORT (single-dose intra-operative radiotherapy)
Study: 26702749
Drug: Art therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art therapy (6 painting sessions)
Study: 25456558
Drug: Setrobuvir 200
Normalized name: Setrobuvir
DrugBank: Setrobuvir (DB12051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setrobuvir 200 mg BID
Study: 25456558
Drug: Setrobuvir 400
Normalized name: Setrobuvir
DrugBank: Setrobuvir (DB12051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setrobuvir 400 mg BID
Study: 25456558
Drug: Setrobuvir 800
Normalized name: Setrobuvir
DrugBank: Setrobuvir (DB12051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setrobuvir 800 mg BID
Study: 15340127
Drug: lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumiracoxib 400 mg/day
Study: 9549655
Drug: (R)-ketoprofen 100
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (R)-ketoprofen 100 mg b.i.d.
Study: 9549655
Drug: (R)-flurbiprofen 100
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (R)-flurbiprofen 100 mg b.i.d.
Study: 9549655
Drug: racemic ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: racemic ketoprofen 100 mg b.i.d.
Study: 9549655
Drug: paracetamol 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol 1,000 mg b.i.d.
Study: 7803063
Drug: Practice models
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Practice models for applying the 1988 Adult Treatment Panel Guidelines
Study: 31933034
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (12-week exercise programme, twice per week)
Study: 29320589
Drug: Test Product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Product (novel hyaluronic acid gel)
Study: 29320589
Drug: Comparator (non‐animal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (non‐animal stabilized hyaluronic acid gel)
Study: 25018057
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (260 mg)
Study: 8879603
Drug: beta-blocker +
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker + diuretics
Study: 10225478
Drug: calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium antagonists
Study: 2271853
Drug: Thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics taken by 325 men for a mean of 11.9 years
Study: 2271853
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive drugs taken by 53 men
Study: 28369211
Drug: GSK3532795 5-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3532795 5-120 mg once daily for 10 days (Part A)
Study: 28369211
Drug: GSK3532795 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3532795 40 mg or 80 mg once daily with atazanavir (ATV) ± ritonavir (RTV) for 28 days (Part B)
Study: 28369211
Drug: GSK3532795 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3532795 40 mg or 120 mg once daily for 10 days (Part C)
Study: 23722951
Drug: Real electroacupuncture
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real electroacupuncture (EA) twice weekly for 6 weeks
Study: 23722951
Drug: Sham electroacupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham electroacupuncture (EA) twice weekly for 6 weeks
Study: 17519278
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with methotrexate (MTX)
Study: 17519278
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with methotrexate (MTX)
Study: 11159760
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g meat/day
Study: 11159760
Drug: 240 g
Normalized name: aspirin 15.6 GM (240 grains) Oral Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 g meat/day
Study: 11159760
Drug: 420 g
Normalized name: GLYCERIN 20 g in 420 g TOPICAL SOAP [Kojic Acid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420 g meat/day
Study: 11159760
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g meat/day
Study: 11159760
Drug: 420 g
Normalized name: GLYCERIN 20 g in 420 g TOPICAL SOAP [Kojic Acid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420 g meat/day for 40 days
Study: 7697230
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination dry powder inhaler (Turbuhaler) containing terbutaline (250 micrograms) with budesonide (200 micrograms)
Study: 11696921
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + irrigation with collagen gel containing 1% chlorhexidine (group 3)
Study: 11696921
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + irrigation with collagen gel (group 2)
Study: 2691317
Drug: Shosaiko-to (SST)
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shosaiko-to (SST) 5.4 g daily for 12 weeks
Study: 2691317
Drug: Placebo 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.5 g of SST for 12 weeks
Study: 26955704
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion (0.05 mg · kg(‐1) · min(‐1) for 24 hours)
Study: 15199073
Drug: telavancin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: telavancin 7.5 mg/kg
Study: 15199073
Drug: telavancin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: telavancin 15 mg/kg
Study: 15199073
Drug: moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin 400 mg (positive control)
Study: 2886533
Drug: Latamoxef at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latamoxef at 6 g day‐1
Study: 2886533
Drug: Latamoxef at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latamoxef at 3 g day‐1
Study: 25439435
Drug: AKB‐9778 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKB‐9778 15 mg or more twice daily
Study: 25439435
Drug: AKB‐9778 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKB‐9778 22.5 mg or more twice daily
Study: 23972322
Drug: Any category
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any category of AREDS treatment
Study: 18512710
Drug: Rituximab (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1,000 mg on days 1 and 15)
Study: 21225699
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti‐CCP antibodies or RF
Study: 21225699
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of RF or anti‐CCP antibodies and elevated IgG